Traditionally, researchers have found it difficult to use RNAi in certain cell types, such as stem cells and non-dividing cells. However, more successful methods for gene knockdown in these cell types are now available.
MISSION shRNA lentiviral particles are pseudotyped with VSV-G protein, which makes it possible to transduce a wide range of cell types, including neuronal cells, tumor cells, monocytes and many more.
In addition, researchers are increasingly using RNAi for in vivo applications. The MISSION lentivirus can be delivered using a variety of methodologies, including intraperitoneal, intravenous, intramuscular, intratumoral and ex vivo routes. Direct injection and ex vivo methods have different advantages, depending on the application and research objectives. Ex vivo delivery is commonly used for applications requiring complete selection of a pure population of transduced cells followed by transplantation. The duration of in vivo knockdown is not expected to be different from that of in vitro applications.
Please explore our learning center to learn more about these and the latest enhancements to traditional methods of transfection and transduction.